var data={"title":"Neostigmine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Neostigmine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6643?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">see &quot;Neostigmine: Drug information&quot;</a> and <a href=\"topic.htm?path=neostigmine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Neostigmine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200742\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bloxiverz</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200743\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Prostigmin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060547\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Neuromuscular Blocking Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Cholinergic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Diagnostic Agent, Myasthenia Gravis</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27867955\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Reversal of nondepolarizing neuromuscular blockade after surgery:</b> IV: <i>Bloxiverz:</i> <b>Note:</b> An anticholinergic agent (atropine or glycopyrrolate) should be given prior to or in conjunction with neostigmine; in the presence of bradycardia, administer the anticholinergic prior to neostigmine. Peripheral nerve stimulation delivering train-of-four (TOF) stimulus must also be used to determine time of neostigmine initiation and need for additional doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Usual dose:</i> 0.03 to 0.07 mg/kg generally achieves a TOF twitch ratio of 90% within 10 to 20 minutes of administration; maximum total dose: 0.07 mg/kg or 5 mg (whichever is less) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Dose selection guide: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The 0.03 mg/kg dose is recommended for reversal of NMBAs with shorter half-lives (eg, rocuronium); or when the first twitch response to the TOF stimulus is substantially &gt;10% of baseline or when a second twitch is present.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The 0.07 mg/kg dose is recommended for NMBAs with longer half-lives (eg, vecuronium, pancuronium); or when the first twitch response is relatively weak (ie, not substantially &gt;10% of baseline); or rapid recovery is needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060541\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">see &quot;Neostigmine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Neostigmine (Prostigmin) tablets have been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myasthenia gravis:</b> Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Diagnosis:</i>\n      <b> Note:</b> Pretreatment with atropine is recommended, and atropine should be available. IV fluids also recommended. Children &lt;2 years: IM: 0.04 mg/kg once; if results equivocal or negative, may be repeated once in 4 hours. Typical dose is 0.5 to 1.5 mg (Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i> <b> Note:</b> Dosage requirements are variable; dosage should be individualized: Children and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 0.3 to 2 mg/kg/day in divided doses (Silvestri 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM, IV, SubQ: 0.01 to 0.04 mg/kg every 2 to 6 hours (Kliegman 2007; Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reversal of nondepolarizing neuromuscular blockade after surgery:</b> Infants, Children, and Adolescents: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer labeling: Bloxiverz: <b>Note:</b> An anticholinergic agent (atropine or glycopyrrolate) should be given prior to or in conjunction with neostigmine; in the presence of bradycardia, administer the anticholinergic prior to neostigmine. Peripheral nerve stimulation delivering train-of-four (TOF) stimulus must also be used to determine time of neostigmine initiation and need for additional doses.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Usual dose:</i> 0.03 to 0.07 mg/kg generally achieves a TOF twitch ratio of 90% within 10 to 20 minutes of administration; maximum total dose: 0.07 mg/kg or 5 mg (whichever is less) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dose selection guide: </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">The 0.03 mg/kg dose is recommended for reversal of NMBAs with shorter half-lives (eg, rocuronium); or when the first twitch response to the TOF stimulus is substantially &gt;10% of baseline or when a second twitch is present.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">The 0.07 mg/kg dose is recommended for NMBAs with longer half-lives (eg, vecuronium, pancuronium); or when the first twitch response is relatively weak (ie, not substantially &gt;10% of baseline); or rapid recovery is needed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Generic injectable products: Limited data available (Kliegman 2007; Nelson 1996): Infants and Children: 0.025 to 0.1 mg/kg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myasthenia gravis:</b> Treatment: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: Usual dose: 150 mg administered over a 24-hour period; interval between doses is of paramount importance and therapy is frequently required day and night. Dosage range: 15 to 375 mg daily in divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM, SubQ: 0.5 mg; subsequent dosing based on individual patient response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternative recommendations (off-label dosing):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: Initial: 15 mg every 8 hours; may increase every 1 to 2 days up to 375 mg daily maximum; interval between doses must be individualized to maximal response</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM, IV, SubQ: 0.5 to 2.5 mg every 1 to 3 hours as needed up to 10 mg/24 hours maximum </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reversal of nondepolarizing neuromuscular blockade after surgery</b> <i>Bloxiverz:</i> IV: <b>Note:</b> An anticholinergic agent (atropine or glycopyrrolate) should be given prior to or in conjunction with neostigmine; in the presence of bradycardia, administer the anticholinergic prior to neostigmine. Peripheral nerve stimulation delivering train-of-four (TOF) stimulus must also be used to determine time of neostigmine initiation and need for additional doses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Usual dose:</i> 0.03 to 0.07 mg/kg generally achieves a TOF twitch ratio of 90% within 10 to 20 minutes of administration; maximum total dose: 0.07 mg/kg or 5 mg (whichever is less) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dose selection guide:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">The 0.03 mg/kg dose is recommended for reversal of NMBAs with shorter half-lives (eg, rocuronium); or when the first twitch response to the TOF stimulus is substantially &gt;10% of baseline or when a second twitch is present.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">The 0.07 mg/kg dose is recommended for NMBAs with longer half-lives (eg, vecuronium, pancuronium); or when the first twitch response is relatively weak (ie, not substantially &gt;10% of baseline); or rapid recovery is needed.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Generic products: IV: 0.5 to 2 mg; repeat as required. Only in exceptional cases should the total dose exceed 5 mg. <b>Note:</b> Administer with atropine 0.6 to 1.2 mg in a separate syringe several minutes before neostigmine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postoperative urinary retention:</b> IM, SubQ: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prevention:</i> 0.25 mg as soon as possible after operation; repeat every 4 to 6 hours for 2 to 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i> 0.5 mg; if urination does not occur within an hour, patient should be catheterized. After the bladder has emptied or patient has voided, continue 0.5 mg every 3 hours for at least 5 doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postoperative bladder distention:</b> IM, SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prevention:</i> 0.25 mg as soon as possible after operation; repeat every 4 to 6 hours for 2 to 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i> 0.5 mg as needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustment provided in manufacturer's labeling; however, the following adjustments have been recommended (Aronoff 2007): Adults: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 50 mL/minute: Administer 50% of normal dose. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: Administer 25% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis: No dosage adjustment necessary </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT): Administer 50% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustment provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200722\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as methylsulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg/mL (10 mL [DSC]); 1 mg/mL (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as methylsulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bloxiverz: 5 mg/10 mL (10 mL); 10 mg/10 mL (10 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/10 mL (10 mL); 10 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as methylsulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/5 mL (5 mL); 2 mg/2 mL (2 mL); 3 mg/3 mL (3 mL); 4 mg/4 mL (4 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200710\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28185877\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Neostigmine (Prostigmin) tablets have been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060551\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: May be administered undiluted by slow IV injection over several minutes; may be administered IM or SubQ </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Divide dosages so patient receives larger doses at times of greatest fatigue; may be administered with or without food</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21024420\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bloxiverz: Store between 20&deg;C and 25&deg;C (68&deg;F and 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. Store in carton until time of use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neostigmine Omega [Canadian product]: Store at 15&deg;C to 30&deg;C; protect from light; multiple use vials should be discarded 28 days after initial use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prostigmin [Canadian product]: Store at 15&deg;C to 30&deg;C; protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Prostigmin [Canadian product]: Store at 15&deg;C to 30&deg;C; protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060550\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Treatment of myasthenia gravis (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Reversal of the effects of nondepolarizing neuromuscular blocking agents after surgery (Bloxiverz; FDA approved in all ages; generic injection: FDA approved in adults); treatment of myasthenia gravis when oral therapy impractical (FDA approved in adults); prevention and treatment of postoperative bladder distention and urinary retention (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200789\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bloxiverz may be confused with Vazculep (phenylephrine injection) due to similar packaging</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Prostigmin may be confused with physostigmine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200786\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrioventricular block, cardiac arrhythmia (especially bradycardia), ECG changes (nonspecific), flushing, hypotension, nodal arrhythmia, syncope, tachycardia, thrombophlebitis (IV)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, drowsiness, dysarthria, headache, loss of consciousness, seizure, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, dysphagia, flatulence, increased peristalsis, nausea, salivation, stomach cramps, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary urgency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, fasciculations, laryngospasm, muscle cramps, muscle spasm, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Lacrimation, miosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, dyspnea, exacerbation of asthma, increased bronchial secretions, respiratory depression, respiratory paralysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200728\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to neostigmine or any component of the formulation; peritonitis or mechanical obstruction of the intestinal or urinary tract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to bromides (tablets only)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for cholinesterase inhibitors is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200714\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular effects: Bradycardia, hypotension, and dysrhythmias may occur, particularly with IV use; risk may be increased in patients with certain cardiovascular conditions (eg, coronary artery disease, cardiac arrhythmias, recent acute coronary syndrome). Risk may also be increased in patients with myasthenia gravis. When IV neostigmine is administered for the reversal of nondepolarizing neuromuscular-blocking agents, atropine or glycopyrrolate should be administered concurrently or prior to neostigmine to lessen the risk of bradycardia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cholinergic crisis: Overdosage may result in cholinergic crisis, characterized by extreme muscle weakness and potentially fatal respiratory paralysis. Cholinergic crisis should be distinguished from myasthenic crisis, which is also characterized by extreme muscle weakness, but would require radically different treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Symptoms of hypersensitivity have included anaphylaxis, angioedema, bradycardia, bronchospasm, erythema multiforme, facial swelling, flushing, generalized rash, hypotension, peripheral edema, pyrexia, and urticaria. Have atropine and epinephrine ready to treat hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular effects: Large doses of IV neostigmine administered for the reversal of nondepolarizing neuromuscular-blocking agents when neuromuscular blockade is minimal can result in neuromuscular dysfunction. Reduce dose if recovery from neuromuscular blockade is nearly complete.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Asthma: Use with caution in patients with asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with bradycardia, cardiac arrhythmias, coronary artery disease, or recent acute coronary syndrome. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Megacolon/GI dysfunction: Large oral doses should be avoided with megacolon or decreased GI motility. Neostigmine may accumulate; toxicity may result when motility is restored.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myasthenia gravis: Adequate facilities should be available for cardiopulmonary resuscitation when testing and adjusting dose for myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peptic ulcer disease: Use with caution in patients with peptic ulcer disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorder: Use with caution in patients with epilepsy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vagotonia: Use with caution in patients with vagotonia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: When used IV for the reversal of nondepolarizing muscle relaxants, pediatric and adult dosing is similar. However, recovery may be more rapid and risk of complications may be greater in infants and small children. Monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution and monitor for a longer period. Elderly patients experience slower spontaneous recovery from neuromuscular blocking agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299756\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200718\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12640&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers. <b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200719\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13855370\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies (doses used were below maximum expected human exposure based on BSA). Anticholinesterases have caused uterine irritability and induced premature labor with IV use in near-term pregnant women. When used as adjunct to analgesia in labor, adverse events to the fetus and mother are dose- and route-dependent (Habib 2006). Neostigmine may be used to treat myasthenia gravis in pregnant women; however, if an acetylcholinesterase inhibitor is needed during pregnancy, another agent may be preferred (Massey 2014; Norwood 2014; Silvestri 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060546\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ECG, blood pressure, and heart rate especially with IV use; consult individual institutional policies and procedures; muscle strength</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200713\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits destruction of acetylcholine by acetylcholinesterase which facilitates transmission of impulses across myoneural junction; direct cholinomimetic effect on skeletal muscle and possible on autonomic ganglion cells and neurons of the CNS</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200727\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Peristaltic activity: Oral: 2 to 4 hours; Parenteral: 10 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: IM: 2.5 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Poor (~1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: IV: 0.12 to 1.4 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 15% to 25% to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Adults: 51 to 90 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Range: 24 to 113 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants 2 to 10 months: Mean: 39 &plusmn; 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 1 to 6 years: Mean: 48 &plusmn; 16 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults 29 to 48 years: 67 &plusmn; 8 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Anephric patients: 181 &plusmn; 54 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Renal transplant patients: 104.7 &plusmn; 64 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Adults: 42 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: 1 to 2 hours (Aquilonius 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (50% as unchanged drug; remainder as metabolites) (Aquilonius 1986)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323488\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bloxiverz Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/10 mL (10 mL): $73.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/10 mL (10 mL): $75.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Neostigmine Methylsulfate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/10 mL (10 mL): $75.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/10 mL (10 mL): $84.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Neostigmine Methylsulfate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/2 mL (2 mL): $25.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg/3 mL (3 mL): $37.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/4 mL (4 mL): $48.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (5 mL): $60.77</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200731\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bloxiverz (BM);</li>\n      <li>Episitgmin (SA);</li>\n      <li>Epistigmin (QA);</li>\n      <li>Fadastigmina (AR);</li>\n      <li>Flextig (BD);</li>\n      <li>Intrastigmina (IL, PT);</li>\n      <li>Metastigmin[inj.] (FI);</li>\n      <li>Miostin (RO);</li>\n      <li>Myostigmin (ET);</li>\n      <li>Neostigmin (HR, SE);</li>\n      <li>Neotalis (PH);</li>\n      <li>Normastigmin (AT);</li>\n      <li>Polstigminum (PL);</li>\n      <li>Prostig (BD, PH);</li>\n      <li>Prostigmin (AE, AT, BB, BF, BH, BJ, BM, BS, BZ, CH, CI, CY, CZ, DE, EC, EG, ET, GH, GM, GN, GY, ID, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PK, PR, PY, QA, SA, SC, SD, SG, SI, SL, SN, SR, SY, TH, TN, TT, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Prostigmin INJ (AU);</li>\n      <li>Prostigmina (IT);</li>\n      <li>Prostigmine (BE, BR, CL, CO, ES, FR, GR, LU, MX, PE, PT, UY, VN);</li>\n      <li>Prostigmin[inj.] (GB, HR, IE);</li>\n      <li>Setisin (MY);</li>\n      <li>Stigmin (KR);</li>\n      <li>Stigmosan (HU);</li>\n      <li>Stignal (BD);</li>\n      <li>Stigvita (LK);</li>\n      <li>Syntostigmin (BG);</li>\n      <li>Tilstigmin (IN, LK);</li>\n      <li>Vagostin (TW);</li>\n      <li>Versia (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bloxiverz injection (neostigmine) [prescribing information]. Chesterfield, MO: &Eacute;clat Pharmaceuticals; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habib AS and Gan TJ, &quot;Use of Neostigmine in the Management of Acute Postoperative Pain and Labour Pain: A Review,&quot; <i>CNS Drugs</i>, 2006, 20(10):821-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neostigmine-pediatric-drug-information/abstract-text/16999453/pubmed\" target=\"_blank\" id=\"16999453\">16999453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson WE, Behrman RE, Kliegman RM, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WB Saunders Company; 1996.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neostimine injection [prescribing information]. Eatontown, NJ: West Ward Pharmaceuticals; October 011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Norwood F, Dhanjal M, Hill M, et al, &quot;Myasthenia in Pregnancy: Best Practice Guidelines From a UK Multispecialty Working Group,&quot; <i>J Neurol Neurosurg Psychiatry</i>, 2013 [epub ahead of print].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prostigmin tablets (neostigmine) [prescribing information]. Aliso Viejo, CA: Valeant Pharmaceuticals North America; August 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silvestri NJ and Wolfe GI, &quot;Myasthenia Gravis,&quot; <i>Semin Neurol</i>, 2012, 32(3):215-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neostigmine-pediatric-drug-information/abstract-text/23117946/pubmed\" target=\"_blank\" id=\"23117946\">23117946</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12640 Version 139.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F200742\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F200743\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060547\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F27867955\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060541\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F200722\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F200710\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F28185877\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060551\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F21024420\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060550\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F200789\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F200786\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F200728\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F200714\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299756\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F200718\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F200719\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13855370\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1060546\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F200713\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F200727\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323488\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F200731\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12640|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">Neostigmine: Drug information</a></li><li><a href=\"topic.htm?path=neostigmine-patient-drug-information\" class=\"drug drug_patient\">Neostigmine: Patient drug information</a></li></ul></div></div>","javascript":null}